Metagenomi, Inc. Common Stock (MGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Metagenomi, Inc. Common Stock (MGX) has a cash flow conversion efficiency ratio of -0.154x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.18 Million) by net assets ($137.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Metagenomi, Inc. Common Stock's balance sheet to measure how much of total assets are equity-financed.
Metagenomi, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Metagenomi, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Metagenomi, Inc. Common Stock total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Metagenomi, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Metagenomi, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YeaRimDang Publishing Co. Ltd
KQ:036000
|
-0.069x |
|
PanGen Biotech Inc
KQ:222110
|
-0.122x |
|
Me2on Co. Ltd
KQ:201490
|
0.027x |
|
N2N Connect Bhd
KLSE:0108
|
0.055x |
|
Eastwood Bio-Medical Canada Inc
V:EBM
|
0.001x |
|
Libental
TA:LBTL
|
-2.455x |
|
ICD Co. Ltd
KQ:040910
|
-0.043x |
|
Metalpha Technology Holding Limited
NASDAQ:MATH
|
0.310x |
Annual Cash Flow Conversion Efficiency for Metagenomi, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Metagenomi, Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see MGX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $158.60 Million | $-88.89 Million | -0.560x | -20.69% |
| 2024-09-30 | $234.86 Million | $-109.07 Million | -0.464x | -9.32% |
| 2023-09-30 | $215.17 Million | $-91.41 Million | -0.425x | -6.37% |
| 2022-09-30 | $-74.43 Million | $29.72 Million | -0.399x | +46.42% |
| 2021-09-30 | $-32.54 Million | $24.26 Million | -0.745x | -- |
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for … Read more